Ionis Pharmaceuticals Reports Late-Stage Study Success for Olezarsen in Lowering Triglycerides and Reducing Acute Pancreatitis Events

Ionis Pharmaceuticals has reported promising results from a late-stage study of its investigational drug olezarsen, branded as Tryngolza. The treatment demonstrated significant efficacy in lowering triglyceride levels among participants while also reducing the incidence of acute pancreatitis events. These findings mark a notable development in the treatment of conditions associated with elevated triglycerides.

The study outcomes suggest that olezarsen may offer dual benefits for patients by addressing both high triglyceride levels and complications such as acute pancreatitis, which can arise from severe hypertriglyceridemia. Analysts at BMO Capital Markets noted that this combination of effects could position olezarsen for a strong commercial launch as a first-in-class therapy. The results are seen as meeting or exceeding expectations for the drug’s performance in this phase of clinical testing. Further details on the study methodology and data analysis have not yet been disclosed.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 3, 2025

Author

Mark Chiang